相关实验视频

Updated: Jun 25, 2025

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

西米卡巴混合值Cu (I/II) 复合物通过多种途径对抗肺腺癌细胞,包括质亡

Aili Li^1,2, Kai Huang^3,4, Weiping Pan¹

¹Laboratory of Respiratory Diseases, The Affiliated Hospital of Guilin Medical University, Guilin 541001, P. R. China.

Journal of medicinal chemistry

|May 23, 2024

概括

新的铜复合体通过诱导细胞死亡途径cuproptosis显示出强大的抗肺癌活性. 复合物2是一种混合价值的铜复合物,在体内表现出低毒性的疗效,为癌症治疗提供了一个有前途的新途径.

科学领域:

药用化学医学化学
癌症生物学癌症生物学
无机化学无机化学

背景情况:

杯和准多个信号通路是瘤治疗中的新兴策略.
西米亚巴-铜复合物已经显示出作为抗癌剂的潜力.

研究的目的:

综合和评估两种新型二氧化碳-铜复合物的抗肺癌活性.
为了研究作用机制,包括诱导cuproptosis,最有前途的复合体.

主要方法:

两个铜复合物的合成: [CuII(L) Cl] (1) 和 [CuII2CuI(L) 2Cl3] (2).
在实验室中对抗肺癌细胞的抗癌活性进行评估,与西斯相比较.
在使用A549细胞的小鼠异种移植模型中,对复合体2的体内评估.
对由复合体2诱导的细胞通路的分析,包括cuproptosis.

主要成果:

这两种铜复合物与西斯普拉丁相比,都表现出更高的抗癌活性.
复合体的血液溶解水平与西斯普拉丁相当.
复合物2在体内有效抑制A549瘤生长,系统毒性最小.
发现复合物2诱导了cuproptosis,并激活了肺癌细胞中的多个细胞死亡途径.

结论:

复合体2是第一个被证明能诱导类似cuproptosis的细胞事件的混合价值Cu (I/II) 复合体.
这项研究强调了混合价值铜复合体作为肺癌有效治疗剂的潜力.
综合体2为开发针对cuproptosis的新型癌症疗法提供了一个有希望的新方向.

更多相关视频

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

相关概念视频

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...